<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071055</url>
  </required_header>
  <id_info>
    <org_study_id>ML29459</org_study_id>
    <nct_id>NCT03071055</nct_id>
  </id_info>
  <brief_title>Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF</brief_title>
  <official_title>Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Therapy Comparing Syringe Preparation Time Using Ranibizumab Vial and Pre-filled Syringe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast Clinical Research Associates, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southeast Clinical Research Associates, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 24 week open label study to assess the efficacy of bi-weekly ranibizumab for
      patients with retinal fluid due to exudative macular degeneration refractory to monthly
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 24 week, open-label, non-randomized, phase II study evaluating intravitreal
      ranibizumab dosed every 14 days in subjects with exudative macular degeneration who have
      persistent intraretinal or subretinal fluid despite chronic monthly anti-VEGF therapy (&gt;6
      months). Subjects must have had a minimum of 5 intravitreal anti-VEGF injections administered
      every 4-6 weeks in the 6 months preceding enrollment.

      Consented, enrolled subjects will receive multiple open-label intravitreal injections of 0.5
      mg ranibizumab administered every 14 days (± 3 days). Subjects who have resolution of fluid
      will convert to monthly ranibizumab for the remainder of the study. If fluid recurs, subjects
      will return to biweekly treatment.

      Patients will be assigned to receive treatment with either ranibizumab vial or PFSs so that
      approximately 10 patients will be treated with each delivery method option, and syringe
      preparation time (SPT) will be measured by an assistant who will be observing the procedure
      and timing with an automated stopwatch.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is mean change in ETDRS BCVA visual acuity</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary outcome measure is mean change in ETDRS BCVA visual acuity at 24 weeks compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of eyes that gain or lose &gt;0 letters at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of eyes that gain or lose &gt;0 letters at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of eyes that gain or lose &gt; 5 letters at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of eyes that gain or lose &gt; 5 letters at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of eyes that gain or lose &gt; 10 letters at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of eyes that gain or lose &gt; 10 letters at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of eyes that gain or lose &gt; 15 letters at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of eyes that gain or lose &gt; 15 letters at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare syringe preparation time (SPT) using ranibizumab vial and pre-filled syringe (PFS) in a real world clinical setting</measure>
    <time_frame>24 weeks</time_frame>
    <description>To compare syringe preparation time (SPT) using ranibizumab vial and pre-filled syringe (PFS) in a real world clinical setting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Proportion of eyes with complete resolution of subretinal fluid and/or intraretinal fluid on SD OCT (macular cube) at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>• Proportion of eyes with complete resolution of subretinal fluid and/or intraretinal fluid on SD OCT (macular cube) at 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Exudative Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ranibizumab 0.5mg in commercially available vial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ranibizumab pre filled-syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ranibizumab 0.5mg in soon to be available pre-filled syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab Injection [Lucentis]</intervention_name>
    <description>intravitreal injection</description>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_label>ranibizumab pre filled-syringe</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 50 years

          -  Exudative age related macular degeneration in study eye involving the fovea

          -  Best Corrected Visual Acuity (by ETDRS) letter score in study eye of &lt; 85 and &gt; 24
             (approximate Snellen equivalent 20/20 to 20/320)

          -  Persistent intraretinal or subretinal fluid on SD OCT despite a minimum of 5
             intravitreal anti-VEGF injections administered every 4-6 weeks in the in the 6 months
             preceding enrollment in the study eye

          -  At least 30 days from last intravitreal anti-VEGF injection in the study eye

        Exclusion Criteria:

          -  Patient who are receiving systemic anti-VEGF or proangiogenic therapy

          -  Patients on chronic high doses corticosteroid therapy (&gt; than 10 mg of oral prednisone
             or equivalent greater than 10 days)

          -  Patients on chronic immunosuppressant therapy

          -  Patients on drugs known to have toxic side effects on the retina e.g.
             hydroxychloroquine

          -  History of intravitreal corticosteroids in study eye within 4 months of baseline

          -  Uncontrolled hypertension (defined as systolic &gt;180 mm Hg and/or diastolic &gt; 100 mm Hg
             while patient is sitting)

          -  History of stroke or APTC event in the previous year

          -  Any intraocular surgery in study eye within 90 days of baseline

          -  Presence of vitreomacular traction in study eye

          -  Presence of significant epiretinal proliferation in study eye

          -  Evidence of active infection in either eye

          -  Uncontrolled glaucoma in the study eye defined as a pressure &gt; 25 mmHg on maximal
             medical therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose and Throat Associates, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela K Price, MPH</last_name>
      <phone>704-295-3393</phone>
      <email>aprice@ceenta.com</email>
    </contact>
    <contact_backup>
      <last_name>Andrew N Antoszyk, MD</last_name>
      <phone>704-295-3390</phone>
      <email>ana@ceenta.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew N. Antoszyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omar S. Punjabi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose and Throat Associates, PA</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela K. Price, MPH</last_name>
      <phone>704-295-3393</phone>
      <email>aprice@ceenta.com</email>
    </contact>
    <contact_backup>
      <last_name>Andrew N. Antoszyk, MD</last_name>
      <phone>704-295-3390</phone>
      <email>ana@ceenta.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew N. Antoszyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omar S. Punjabi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John B. Allen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2017</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast Clinical Research Associates, LLC</investigator_affiliation>
    <investigator_full_name>Andrew N. Antoszyk, MD</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Macular Degeneration</keyword>
  <keyword>AMD</keyword>
  <keyword>Wet AMD</keyword>
  <keyword>Lucentis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Papilledema</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

